Cell Surface Markers Market Size, Share & Industry Analysis, By Product (Antibody, PCR Array), By Source (Human, Mouse, Rat, Others) , By Application (Research, Clinical, Others), By End User (Research Institutes, Pharmaceutical & Biotechnology Industry, Others) and Regional Forecast, 2024-2032

Proteins and carbohydrates attached to the cell membrane are known as cell surface markers. The cell surface markers help identifying the specific type of cell which is useful in studying various diseases. As per world health organization (WHO), globally about 9.6 million deaths occur due to cancer. Cell surface markers are a crucial aspect in studying oncology and hence are in greater demand. Extensive R&D in research institutes, pharmaceutical companies, and CROs has led to the increasing demand for cell surface markers such as PCR array and antibodies. Demand for effective drugs against chronic diseases is also the factor leading to the growth of cell surface markers market. Moreover, the markers help in identifying the ligands or the drug response which may prove useful in development of drugs. Depending on the immune response initiated by the cell type for a particular disease, researchers choose cell surface markers based on T-cell, B-cell or NK cells. Thus, surge in funding for R&D is the key factor for the market growth of the global cell surface markers.

The major factor driving the global cell surface markers market is investments in R&D for continuous launch of effective medicines and develop therapies such as stem cell, immunotherapy etc. Other factors driving the market includes an introduction of innovative and effective cell surface markers by the pharmaceutical & biotechnology industries to carry an extensive research.

On the flip side, to carry out the desired research the individual firm needs to invest in expensive instruments and reagents. But, start-ups and small scale industries lack financial resources, hence tend to minimise the use of expensive instruments ultimately affecting the sales of cell surface markers.

Market Segmentation:

By product, the market is segmented into antibodies and PCR array. Based on source, the market is segmented into human, mouse, rat, and others. Based on application, the market is categorised into research, clinical, and others. Based on end users, the cell surface markers market is segmented into research institutes, pharmaceutical & biotechnology industries, and others.

From a geographical standpoint, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Key Players Covered:

The major companies in the global cell surface markers market report includes Thermo Fisher Scientific, QIAGEN N.V., Bio-Rad Laboratories, F. Hoffman-La Roche, BD, Grifols SA, GenScript, Siemens Healthcare Private Limited,  Abcam plc., and others.

Key Insights

• New Advancements In Cell Surface Markers Market


• Pipeline Analysis


• Prevalence of Major Chronic Diseases – By Key Countries./Regions


• Key Industry Developments – Mergers, Acquisitions, and Partnerships

Regional Analysis:

The global cell surface markers market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America followed by Europe dominated the global cell surface markers market in 2019, owing to the rise in R&D of the pharmaceutical & biotechnology industries. However, increasing patient pool suffering from chronic disease and demand for effective medications in Asia Pacific is likely to accelerate the growth of the market in this regions. This along with growing mergers and acquisitions between industry players and funds allotment by the regional and national government agencies, to promote the sales of the cell surface markers in countries like China, India, and other countries, is projected to further augment the demand for cell surface markers in Asia Pacific. Latin America and Middle East & Africa are projected to register a comparatively lower CAGR by the end of the forecast period.

Segmentation

Cell Surface Markers Industry Developments

• In April 2016, Abnova Corporation received worldwide license to CSV (Cell-surface vimentin) monoclonal antibody for cancer-specific circulating tumor cells from MD Anderson Cancer Center.


• In December 2019, Neuro-sys SAS company entered into a partnership agreement with Sciomis GmbH to collaboratively develop solution for neurodegenerative disorders. Sciomis has expertise in biomarker discovery. This platform of the company will help Neuro-sys SAS for developing the solution.